vitamin K deficiency hemorrhagic disease

Summary

vitamin K deficiency hemorrhagic disease (MONDO:0001244) is a disease and 7 clinical trials. Top therapeutic interventions include phytonadione. A subtype of vitamin deficiency disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vitamin K deficiency hemorrhagic disease
Mondo ID	MONDO:0001244
MeSH	D014813
DOID	DOID:11249
ICD-10-CM	E56.1
NCIT	C99108
SNOMED CT	52675005
UMLS	C0272348
MedGen	543992
Is cancer (heuristic)	no

Also known as: deficiency of vitamin K · vitamin K deficiency · vitamin K deficiency coagulation disorder

Disease family

This is a subtype of vitamin deficiency disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › nutritional disorder › nutritional deficiency disease › vitamin deficiency disorder › vitamin K deficiency hemorrhagic disease

Related subtypes (7): nutritional biotin deficiency, inborn vitamin metabolic disorder, vitamin A deficiency, scurvy, vitamin B deficiency, vitamin D deficiency, vitamin deficiency related neuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Phytonadione	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05943457	Not specified	RECRUITING	Vitamin K2 Supplementation in Adult Episodic Migraine
NCT03311321	Not specified	UNKNOWN	Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
NCT03782025	Not specified	COMPLETED	Effect of Vitamin K in Critically Ill Patients
NCT04188080	Not specified	COMPLETED	Estimation of a Maintaining Daily Jarlsberg Cheese-dose
NCT04517461	Not specified	COMPLETED	Coagulation and Vitamin K in Head and Neck Microvascular Free Flap Surgery
NCT04900610	Not specified	UNKNOWN	The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
NCT05360342	Not specified	COMPLETED	Incorporation of Vitamin K Into Uremic Lipoproteins

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PHYTONADIONE	4	1
CHEMBL520156	0	1